西岡 安彦 にしおか やすひこ 先生

来歴等

略歴

1995年 徳島大学医学部内科学第三講座 助手
1996年 米国ピッツバーグ大学外科学・分子遺伝学・生化学部門 研究員
1999年 徳島大学医学部内科学第三講座 講師
2007年 徳島大学大学院ヘルスバイオサイエンス研究部分子制御内科学分野 准教授
2011年 徳島大学大学院ヘルスバイオサイエンス研究部（現 医歯薬学研究部） 呼吸器・膠原病内科学分野 教授

もっと見る

論文

• 1. Down-regulation by interleukin 4 of activation of human alveolar macrophages to the tumoricidal state. Cancer Res 51(10):5526-5531, 1991.

  Nishioka Y, Sone S, Orino E, Nii A, Ogura T.

• 2. The a-type 85-kDa subunit of phosphatidylinositol 3-kinase is phosphorylated at tyrosines 368, 580, and 607 by the insulin receptor. J Biol Chem 268(10):7107-7117, 1993.

  Hayashi H, Nishioka Y, Kamohara S, Kanai F, Ishii K, Fukui Y, Shibasaki F, Takenawa T, Kido H, Katsunuma N, Ebina Y.

• 3. Direct demonstration of insulin-induced GLUT4 translocation to the surface of intact cells by insertion of a c-myc epitope into an exofacial GLUT4 domain. J Biol Chem 268(19):14523-14526, 1993.

  Kanai F, Nishioka Y, Hayashi H, Kamohara S, Todaka M, Ebina Y.

• 4. Combined therapy of multidrug-resistant human lung cancer with anti-P-glycoprotein antibody and monocyte chemoattractant protein-1 gene transduction: the possibility of immunological overcoming of multidrug resistance. Int J Cancer 71(2):170-177, 1997.

  Nishioka Y, Yano S, Fujiki F, Mukaida N, Matsushima K, Tsuruo T, Sone S.

• 5. Induction of systemic and therapeutic antitumor immunity using intratumoral injection of dendritic cells genetically modified to express interleukin 12. Cancer Res 59(16):4035-4041, 1999.

  Nishioka Y, Hirao M, Robbins PD, Lotze MT, Tahara H.

• 6. Human monocyte-derived and CD83+ blood dendritic cells enhance NK cell-mediated cytotoxicity. Eur J Immunol 31(9):2633-2641, 2001.

  Nishioka Y, Nishimura N, Suzuki Y, Sone S.

• 7. Imatinib as a novel antifibrotic agent in bleomycin-induced pulmonary fibrosis in mice. Am J Respir Crit Care Med 171:1279-1285, 2005.

  Aono Y, Nishioka Y, Inayama M, Kishi J, Ugai M, Uehara H, Izumi K, Sone, S.

• 8. A Novel IkB kinase-b inhibitor ameliorates bleomycin-induced pulmonary fibrosis in mice. Am J Respir Crit Care Med 173(9):1016-1022, 2006.

  Inayama M, Nishioka Y, Azuma M, Muto S, Aono Y, Makino H, Tani K, Uehara H, Izumi K, Itai A, Sone S.

• 9. Role of a1-acid glycoprotein in therapeutic antifibrotic effects of imatinib with macrolides in mice. Am J Respir Crit Care Med 176(12):1243-1250, 2007.

  Azuma M, Nishioka Y, Aono Y, Inayama M, Makino H, Kishi J, Shono M, Kinoshita K, Uehara H, Ogushi F, Izumi K, Sone S.

• 10. Blockade of Th1 chemokine receptors ameriolates pulmonary granulomatosis in mice. Eur Respir J. 38(2):415-424, 2011.

  Kishi J, Nishioka Y, Kuwahara T, Kakiuchi S, Azuma M, Aono Y, Makino H, Kinoshita K, Kishi M, Batmunkh R, Uehara H, Izumi K, Sone S.

• 11. Antifibrotic effects of focal adhesion klinase inhibitor in bleomycin-induced pulmonary fibrosis in mice. Am J Respir Cell Mol Biol 49:536-543, 2013.

  Kinoshita K, Aono Y, Azuma M, Kishi J, Takezaki A, Kishi M, Makino H, Okazaki H, Uehara H, Izumi K, Sone S, Nishioka Y.

• 12. Role of PDGF/PDGFR axis in the trafficking of circulating fibrocytes in pulmonary fibrosis. Am J Respir Cell Mol Biol. 51(6):793-801, 2014.

  Aono Y, Kishi M, Yokota Y, Azuma M, Kinoshita K, Takezaki A, Sato S, Kawano H, Kishi J, Goto H, Uehara H, Izumi K, Nishioka Y.

• 13. Thymidine phosphorylase regulates the expression of CXCL10 in rheumatoid arthritis fibroblast-like synoviocytes Arthritis Rheum. 66(3):560-568, 2014.

  Toyoda Y, Tabata S, Kishi J, Kuramoto T, Mitsuhashi A, Saijo A, Kawano H, Goto H, Aono Y, Hanibuchi M, Horikawa H, Nakajima T, Furukawa T, Sone S, Akiyama SI, Nishioka Y.

• 14. Fibrocyte-like cells mediate acquired resistance to anti-angiogenic therapy with bevacizumab. Nat Commun 6:8792, 2015.

  Mitsuhashi A, Goto H, Saijo A, Trung VT, Aono Y, Ogino H, Kuramoto T, Tabata S, Uehara H, Izumi K, Yoshida M, Kobayashi H, Takahashi H, Gotoh M, Kakiuchi S, Hanibuchi M, Yano S, Yokomise H, Sakiyama S, Nishioka Y.

• 15. Anti-fibrotic efficacy of nintedanib in pulmonary fibrosis via the inhibition of fibrocyte activity. Respir Res 18:172, 2017.

  Sato S, Shinohara S, Hayashi S, Morizumi S, Abe S, Okazaki H, Chen Y, Goto H, Aono Y, Ogawa H, Koyama K, Nishimura H, Kawano H, Toyoda Y, Uehara H, Nishioka Y.

• 16. Bone marrow-derived fibrocytes promote stem cell-like properties of lung cancer cells. Cancer Lett 421:17-27, 2018.

  Saijo A, Goto H, Nakano M, Mitsuhashi A, Aono Y, Hanibuchi M, Ogawa H, Uehara H, Kondo K, Nishioka Y.

• 17. Biomarkers of extracellular matrix turnover in patients with idiopathic pulmonary fibrosis given nintedanib (INMARK study): a randomised, placebo-controlled study. Lancet Respir Med 7(9):771-779, 2019.

  Maher TM, Stowasser S, Nishioka Y, White ES, Cottin V, Noth I, Selman M, Rohr KB, Michael A, Ittrich C, Diefenbach C, Jenkins RG: on behalf of the INMARK trial investigators.

• 18. Novel multiple tyrosine kinase inhibitor TAS-115 attenuates bleomycin-induced lung fibrosis in mice. Am J Respir Cell Mol Biol 60(4):478-487, 2019.

  Koyama K, Goto H, Morizumi S, Kagawa K, Nishimura H, Sato S, Kawano H, Toyoda Y, Ogawa H, Homma S, Nishioka Y.

• 19. Blockade of pan-fibroblast growth factor receptors mediates bidirectional effects in lung fibrosis. Am J Respir Cell Moll Biol 63(3):317-326, 2020.

  Morizumi S, Sato S, Koyama K, Okazaki H, Chen Y, Goto H, Aono Y, Ogawa H, Nishimura H, Kawano H, Toyoda Y, Uehara H, Nishioka Y.

• 20. Blockade of PD-1/PD-L1 pathway enhances the antigen-presenting capacity of fibrocytes. J Immunol 206(6):1204-1214, 2021.

  Afroj T, Mitsuhashi A, Ogino H, Saijo A, Otsuka K, Yoneda H, Tobiume M, Nguyen TN, Goto H, Koyama K, Sugimoto M, Kondoh O, Nokihara H, Nishioka Y.

• 21. Nationwide retrospective observational study of idiopathic dendriform pulmonary ossification: clinical features with a progressive phenotype. BMJ Open Respir Res 9(1):e001337, 2022.

  Nishioka Y, Toyoda Y, Egashira R, Johkoh T, Terasaki Y, Hebisawa A, Abe K, Baba T, Fujikura Y, Fujita E, Hamada N, Handa T, Hasegawa Y, Hidaka K, Hisada T, Hisata S, Honjo C, Ichikado K, Inoue Y, Izumi S, Kato M, Kishimoto T, Okamoto M, Miki K, Mineshita M, Nakamura Y, Sakamoto S, Sano M, Tsukada Y, Yamasue M, Bando Y, Homma S, Hagiwara K, Suda T, Inase N.

• 22. Identification of fibrocyte cluster in tumors reveals the role in antitumor immunity by PD-L1 blockade. Cell Rep 42(3):112162, 2023.

  Mitsuhashi A, Koyama K, Ogino H, Afroj T, Nguyen NT, Yoneda H, Otsuka K, Sugimoto M, Kondoh O, Nokihara H, Hanibuchi M, Takizawa H, Shinohara T, Nishioka Y.

• 23. Exploratory phase 2 study of TAS-115, a novel oral multikinase inhibitor, in patients with idiopathic pulmonary fibrosis. Respir Investig 61(4):498-507, 2023.

  Nishioka Y, Homma S, Ogura T, Sato S, Arai N, Tomii K, Kamio K, Sakamoto S, Miyazaki Y, Tomioka H, Hisata S, Handa T, Azuma A.

• 24. A polo-like kinase inhibitor identified by computational repositioning attenuates pulmonary fibrosis. Respir Res 24(1):148, 2023.

  Imakura T, Sato S, Koyama K, Ogawa H, Niimura T, Murakami K, Yamashita Y, Haji K, Naito N, Kagawa K, Kawano H, Zamami Y, Ishizawa K, Nishioka Y.

• 25. Pamufetinib (TAS-115) for Chronic Fibrosing Interstitial Lung Diseases with a Progressive Phenotype: A double-blind, multicenter, phase 2b Clinical Trial. Am J Respir Crit Care Med 12(8):1770-1777, 2026.

  Okuda R, Nishioka Y, Kondoh Y, Tsubouchi K, Okamoto M, Nishiyama O, Sato S, Oishi K, Ishikawa N, Chiba H, Miyazaki Y, Homma S, Ogura T, Inoue Y, Azuma A.

もっと見る

受賞

• 1. 1996年 日米癌研究訓練計画 奨励賞

• 2. 2000年 第38回 日本癌治療学会総会 優秀演題賞

• 3. 2023年 第60回 ベルツ賞 1等賞